mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000
View company profile
Please contact the Account Manager for opportunities with this organisation

Eisai launches Lusedra injection

Posted on 18/11/2009 in Pharmaceutical Company Product News

Eisai has launched its latest therapy this week - the Lusedra (fospropofol disodium) injection.

The treatment is designed for use in patients in need of an intravenous sedative-hypnotic agent.

It is to be used by healthcare professionals trained in the administration of general anaesthesias.

Lusedra is a proprietary water-soluble prodrug of propofol that is converted by alkaline phosphatase enzymes in the body after intravenous injection and is to be administered before sedative effects.

The product was approved in December 2008 by the Food and Drug Administration for use in patients undergoing diagnostic or therapeutic procedures.

In other Eisia news, the organisation revealed earlier this month that a trial into its metastatic breast cancer treatment E7389 (eribulin mesylate) achieved its primary endpoint.

As part of the study, 762 patients were administered either eribulin or one treatment of their choice - including single agent chemotherapy, hormonal treatment or biological therapy.

Other news stories from 18/11/2009

Read more in the Zenopa News Archive

How this news is generated

Jo-Anne
Account Manager
for this opportunity

01494 818 012
(Mon to Fri 0830 to 1800 hours)
jo@zenopa.com

Latest News

Eisai Limited commences new biologics plant construction

Eisai announces acquisition of AkaRx

Eisai introduces Aricept in oral jelly form

Eisai Aricept tablets accepted for FDA review

Eisai launches Lusedra injection

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use